Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2007:106–120. doi: 10.1007/978-0-387-76842-7_10

The Efficacy of Vaccines to Prevent Infectious Diseases in the Elderly

Dietmar Herndler-Brandstetter 2, Beatrix Grubeck-Loebenstein 2
PMCID: PMC7121339

Abstract

Infectious diseases still represent a major challenge to human progress and survival. Especially elderly persons are more frequently and severely affected by infectious diseases and they display distinct features with respect to clinical presentation and treatment. Although vaccinations are considered a vital medical procedure for preventing morbidity and mortality caused by infectious diseases, the protective effect of vaccinations is abrogated in elderly persons. This is due to a decline in the functions of the immune system referred to as immunosenescence. The first part of this chapter will therefore summarize the status quo of the efficacy of vaccines in preventing morbidity and mortality caused by typical infectious diseases in the elderly, such as influenza, pneumonia and tuberculosis. The second part will then elucidate the underlying age-related mechanisms which may contribute to the decreased efficacy of vaccines. Based on the complex mechanisms involved in immunosenescence, strategies will be outlined which may be succesfful in enhancing protective immune responses following vaccination in elderly persons.

Keywords: Influenza Virus, Herpes Zoster, Elderly Person, Severe Acute Respiratory Syndrome, Influenza Vaccine

References

  • 1.Anderson R.N., Smith B.L. Deaths: leading causes for 2002. Natl Vital Stat Rep. 2005;53(17):1–89. [PubMed] [Google Scholar]
  • 2.Weiss R.A., McMichael A.J. Social and environmental risk factors in the emergence of infectious diseases. nat Med. 2004;10(12 Suppl):70–76. doi: 10.1038/nm1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis. 1982;4(5):916–930. doi: 10.1093/clinids/4.5.916. [DOI] [PubMed] [Google Scholar]
  • 5.Pharmaceutical Research and Manufacturers of America, 2004 Survey: New Medicines in development for Infectious diseases, http://www.phrma.org/newmedicines/resources/2004-04-22.130.pdf 2004.
  • 6.Gavazzi G., Krause K.H. Ageing and infection. Lancet Infect Dis. 2002;2(11):659–666. doi: 10.1016/S1473-3099(02)00437-1. [DOI] [PubMed] [Google Scholar]
  • 7.barker W.H., Mullooly J.P. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med. 1982;142(1):85–89. doi: 10.1001/archinte.142.1.85. [DOI] [PubMed] [Google Scholar]
  • 8.Influenza and pneumococcal vaccination coverage among persons aged > or=65 years and persons aged 18–64 years with diabetes or asthma—United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53(43):1007–1012. [PubMed]
  • 9.Gross P.A., Hermogenes A.W., Sacks H.S., et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123(7):518–527. doi: 10.7326/0003-4819-123-7-199510010-00008. [DOI] [PubMed] [Google Scholar]
  • 10.Bouree P. Immunity and immunization in elderly. Pathol Biol (Paris) 2003;51(10):581–585. doi: 10.1016/j.patbio.2003.09.004. [DOI] [PubMed] [Google Scholar]
  • 11.Nichol K.L., Margolis K.L., Wuorenma J., et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331(12):778–784. doi: 10.1056/NEJM199409223311206. [DOI] [PubMed] [Google Scholar]
  • 12.Mullooly J.P., Bennett M.D., Hornbrook M.C., et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994;121(12):947–952. doi: 10.7326/0003-4819-121-12-199412150-00008. [DOI] [PubMed] [Google Scholar]
  • 13.Ahmed A.E., Nicholson K.G., Nguyen-Van-Tam J.S. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet. 1995;346(8975):591–595. doi: 10.1016/S0140-6736(95)91434-X. [DOI] [PubMed] [Google Scholar]
  • 14.Iob A., Brianti G., Zamparo E., et al. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005;133(4):687–693. doi: 10.1017/S0950268805003936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gluck R., Mischler R., Finkel B., et al. Immunogenicity of new virosome infuenza vaccine in elderly people. Lancet. 1994;344(8916):160–163. doi: 10.1016/S0140-6736(94)92758-8. [DOI] [PubMed] [Google Scholar]
  • 16.Conne P., Gauthey L., Vernet P., et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 1997;15(15):1675–1679. doi: 10.1016/S0264-410X(97)00087-X. [DOI] [PubMed] [Google Scholar]
  • 17.Ruf B.R., Colberg K., Frick M., et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection. 2004;32(4):191–198. doi: 10.1007/s15010-004-3204-z. [DOI] [PubMed] [Google Scholar]
  • 18.de Bruijn I.A., Nauta J., Cramer W.C., et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine. 2005;23(Suppl 1):39–49. doi: 10.1016/j.vaccine.2005.04.020. [DOI] [PubMed] [Google Scholar]
  • 19.Ruben F.L. Inactivated influenza virus vaccines in children. Clin Infect Dis. 2004;38(5):678–688. doi: 10.1086/382883. [DOI] [PubMed] [Google Scholar]
  • 20.Reichert T.A., Sugaya N., Fedson D.S., et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;334(2):889–896. doi: 10.1056/NEJM200103223441204. [DOI] [PubMed] [Google Scholar]
  • 21.EARSS Annual Report, available at: http://www.earss.rivm.nl/PAGINA/DOC/rep2002/annual-report-2002.pdf.2002.
  • 22.Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol. 2004;19(4):353–363. doi: 10.1023/B:EJEP.0000024701.94769.98. [DOI] [PubMed] [Google Scholar]
  • 23.Wagner C., Popp W., Posch M., et al. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology. 2003;49(4):246–250. doi: 10.1159/000070405. [DOI] [PubMed] [Google Scholar]
  • 24.Lexau C.A., Lynfield R., Danila R., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Jama. 2005;294(16):2043–2051. doi: 10.1001/jama.294.16.2043. [DOI] [PubMed] [Google Scholar]
  • 25.Dutt A.K., Stead W.W. Tuberculosis. Clin Geriatr Med. 1992;8(4):761–775. [PubMed] [Google Scholar]
  • 26.Rajagopalan S., Yoshikawa T.T. Tuberculosis in the elderly. Z Gerontol Geriatr. 2000;33(5):374–380. doi: 10.1007/s003910070034. [DOI] [PubMed] [Google Scholar]
  • 27.WHO. AntiTB drug resistance in the world. Report no.2. Prevalence and trends. Geneva. Report No.: WHO/CDS/TB/2000.278. 2000.
  • 28.Colditz G.A., Brewer T.F., Berkey C.S., et al. Efficacy of BCG vaccine in the prevention of tubereulosis. Meta-analysis of the published literature. Jama. 1994;271(9):698–702. doi: 10.1001/jama.271.9.698. [DOI] [PubMed] [Google Scholar]
  • 29.McShane H. Coinfection with HIV and TB: double trouble. Int J STD AIDS. 2005;16(2):95–100. doi: 10.1258/0956462053057576. [DOI] [PubMed] [Google Scholar]
  • 30.Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19:93–129. doi: 10.1146/annurev.immunol.19.1.93. [DOI] [PubMed] [Google Scholar]
  • 31.Ragozzino M.W., Melton L. 3., Kurland L.T., et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61(5):310–316. doi: 10.1097/00005792-198209000-00003. [DOI] [PubMed] [Google Scholar]
  • 32.Arvin A.M. Varicella-Zoster virus: pathogenesis, immunity and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2000;6(3):219–230. doi: 10.1016/S1083-8791(00)70004-8. [DOI] [PubMed] [Google Scholar]
  • 33.Mehta S.K., Cohrs R.J., Forghani B., et al. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol. 2004;72(1):174–179. doi: 10.1002/jmv.10555. [DOI] [PubMed] [Google Scholar]
  • 34.Arvin A.M., Gershon A.A. Live attenuated varicella vaccine. Annu Rev Microbiol. 1996;50:59–100. doi: 10.1146/annurev.micro.50.1.59. [DOI] [PubMed] [Google Scholar]
  • 35.Weir E. Vaccination boosts adult immunity to varicella zoster virus. Cmaj. 2005;173(3):249. doi: 10.1503/cmaj.050764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284. doi: 10.1056/NEJMoa051016. [DOI] [PubMed] [Google Scholar]
  • 37.Almanzar G., Schwaiger S., Jenewein B., et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005;79(6):3675–3683. doi: 10.1128/JVI.79.6.3675-3683.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Pawelec G., Akbar A., Caruso C., et al. Human immunosenescence: is it infectious? Immunol Rev. 2005;205:257–268. doi: 10.1111/j.0105-2896.2005.00271.x. [DOI] [PubMed] [Google Scholar]
  • 39.Ouyang Q., Wagner W.M., Zheng W., et al. Dysfunctional CMV-specific CD8+ T-cells accumulate in the elderly. Exp Gerontol. 2004;39(4):607–613. doi: 10.1016/j.exger.2003.11.016. [DOI] [PubMed] [Google Scholar]
  • 40.Holtappels R., Podlech J., Pahl-Seibert M.F., et al. Cytomegalovirus misleads its host by priming of CD8 T-cells specific for an epitope not presented in infected tissues. J Exp Med. 2004;199(1):131–136. doi: 10.1084/jem.20031582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Khan N., Shariff N., Cobbold M., et al. Cytomegalovirus seropositivity drives the CD8 T-cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169(4):1984–1992. doi: 10.4049/jimmunol.169.4.1984. [DOI] [PubMed] [Google Scholar]
  • 42.Franceschi C., Bonafe M., Valensin S., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254. doi: 10.1111/j.1749-6632.2000.tb06651.x. [DOI] [PubMed] [Google Scholar]
  • 43.Saurwein-Teissl M., Lung T.L., Marx F., et al. Lack of antibody production following immunization in old age: association with CD8+CD28− T-cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002;168(11):5893–5899. doi: 10.4049/jimmunol.168.11.5893. [DOI] [PubMed] [Google Scholar]
  • 44.Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science. 1992;257(5067):238–241. doi: 10.1126/science.1352912. [DOI] [PubMed] [Google Scholar]
  • 45.Cherry J.D. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115(5):1422–1427. doi: 10.1542/peds.2004-2648. [DOI] [PubMed] [Google Scholar]
  • 46.Mertens P.L., Stals F.S., Schellekens J.F., et al. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis. 1999;18(4):242–247. doi: 10.1007/s100960050271. [DOI] [PubMed] [Google Scholar]
  • 47.Steger M.M., Maczek C., Berger P., et al. Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection. Lancet. 1996;348(9029):762. doi: 10.1016/S0140-6736(05)65680-2. [DOI] [PubMed] [Google Scholar]
  • 48.Grubeck-Loebenstein B., Berger P., Saurwein-Teissl M., et al. No immunity for the elderly. Nat Med. 1998;4(8):870. doi: 10.1038/nm0898-870b. [DOI] [PubMed] [Google Scholar]
  • 49.Gergen P.J., McQuillan G.M., Kiely M., et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332(12):761–766. doi: 10.1056/NEJM199503233321201. [DOI] [PubMed] [Google Scholar]
  • 50.Gomez I., Marx F., Gould E.A., et al. T-cells from elderly persons respond to neoantigenic stimulation with an unimpaired IL-2 production and an enhanced differentiation into effector cells. Exp Gerontol. 2004;39(4):597–605. doi: 10.1016/j.exger.2003.11.018. [DOI] [PubMed] [Google Scholar]
  • 51.Suss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine. 2003;21(Suppl 1):19–35. doi: 10.1016/S0264-410X(02)00812-5. [DOI] [PubMed] [Google Scholar]
  • 52.Kunz C. TBE vaccination and the Austrian experience. Vaccine. 2003;21(Suppl 1):50–55. doi: 10.1016/S0264-410X(02)00813-7. [DOI] [PubMed] [Google Scholar]
  • 53.Rendi-Wagner P., Kundi M., Zent O., et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine. 2004;23(4):427–434. doi: 10.1016/j.vaccine.2004.07.002. [DOI] [PubMed] [Google Scholar]
  • 54.Steffen R., Kane M.A., Shapiro C.N., et al. Epidemiology and prevention of hepatitis A in travelers. Jama. 1994;272(11):885–889. doi: 10.1001/jama.272.11.885. [DOI] [PubMed] [Google Scholar]
  • 55.Steffen R. Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations. Vaccine. 1993;11(5):518–520. doi: 10.1016/0264-410X(93)90221-I. [DOI] [PubMed] [Google Scholar]
  • 56.Joines R.W., Blatter M., Abraham B., et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 2001;19(32):4710–4719. doi: 10.1016/S0264-410X(01)00240-7. [DOI] [PubMed] [Google Scholar]
  • 57.Hopperus Buma A.P., van Doornum G.J., Veltink R.L., et al. Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops. Vaccine. 1997;15(12–13):1413–1417. doi: 10.1016/S0264-410X(97)00048-0. [DOI] [PubMed] [Google Scholar]
  • 58.Wolters B., Junge U., Dziuba S., et al. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21(25–26):3623–3628. doi: 10.1016/S0264-410X(03)00399-2. [DOI] [PubMed] [Google Scholar]
  • 59.Reuman P.D., Kubilis P., Hurni W., et al. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine. 1997;15(10):1157–1161. doi: 10.1016/S0264-410X(96)00310-6. [DOI] [PubMed] [Google Scholar]
  • 60.WHO. District guidelines for yellow fever surveillance. Geneva, Switzerland. Available at http://www. who.int/emc-documents/yellow_fever/whoepigen9809c.html. 1998.
  • 61.Poland J.D., Calisher C.H., Monath T.P., et al. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895–900. [PMC free article] [PubMed] [Google Scholar]
  • 62.Martin M., Weld L.H., Tsai T.F., et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001;7(6):945–951. doi: 10.3201/eid0706.010605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Aspinall R., Rew D. Thymic involution in aging. J Clin Immunol. 2000;20(4):250–256. doi: 10.1023/A:1006611518223. [DOI] [PubMed] [Google Scholar]
  • 64.George A.J., Ritter M.A. Thymic involution with ageing: obsolescence or good housekeeping? Immunol Today. 1996;17(6):267–272. doi: 10.1016/0167-5699(96)80543-3. [DOI] [PubMed] [Google Scholar]
  • 65.Lazuardi L., Jenewein B., Wolf A.M., et al. Age-related loss of naive T-cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114(1):37–43. doi: 10.1111/j.1365-2567.2004.02006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Zanni F., Vescovini R., Biasini C., et al. Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T-cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol. 2003;38(9):981–987. doi: 10.1016/S0531-5565(03)00160-8. [DOI] [PubMed] [Google Scholar]
  • 67.Grubeck-Loebenstein B., Wick G. The aging of the immune system. Adv Immunol. 2002;80:243–284. doi: 10.1016/S0065-2776(02)80017-7. [DOI] [PubMed] [Google Scholar]
  • 68.Effros R.B., Cai Z., Linton P.J. CD8 T-cells and aging. Crit Rev Immunol. 2003;23(1–2):45–64. doi: 10.1615/CritRevImmunol.v23.i12.30. [DOI] [PubMed] [Google Scholar]
  • 69.Goronzy J.J., Fulbright J.W., Crowson C.S., et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75(24):12182–12187. doi: 10.1128/JVI.75.24.12182-12187.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Shoenfeld Y., Sherer Y., Harats D. Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001;22(6):293–295. doi: 10.1016/S1471-4906(01)01922-6. [DOI] [PubMed] [Google Scholar]
  • 71.Weyand C.M., Fulbright J.W., Goronzy J.J. Immunosenescence, autoimmunity and rheumatoid arthritis. Exp Gerontol. 2003;38(8):833–841. doi: 10.1016/S0531-5565(03)00090-1. [DOI] [PubMed] [Google Scholar]
  • 72.Blasko I., Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer’s disease. Drugs Aging. 2003;20(2):101–113. doi: 10.2165/00002512-200320020-00002. [DOI] [PubMed] [Google Scholar]
  • 73.Blasko I., Stampfer-Kountchev M., Robatscher P., et al. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3(4):169–176. doi: 10.1111/j.1474-9728.2004.00101.x. [DOI] [PubMed] [Google Scholar]
  • 74.Labrie J. 3., Sah A.P., Allman D.M., et al. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B-cell generation in aged mice. J Exp Med. 2004;200(4):411–423. doi: 10.1084/jem.20040845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Weksler M.E., Szabo P. The effect of age on the B-cell repertoire. J Clin Immunol. 2000;20(4):240–249. doi: 10.1023/A:1006659401385. [DOI] [PubMed] [Google Scholar]
  • 76.Johnson S.A., Cambier J.C. Ageing, autoimmunity and arthritis: senescence of the B-cell compartment-implications for humoral immunity. Arthritis Res Ther. 2004;6(4):131–139. doi: 10.1186/ar1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Aydar Y., Balogh P., Tew J.G., et al. Age-related depression of FDC accessory functions and CD21 ligand-mediated repair of costimulation. Eur J Immunol. 2002;32(10):2817–2826. doi: 10.1002/1521-4141(2002010)32:10<2817::AID-IMMU2817>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  • 78.Colonna-Romano G., Bulati M., Aquino A., et al. B-cells in the aged: CD27, CD5 and CD40 expression. Mech Ageing Dev. 2003;124(4):389–393. doi: 10.1016/S0047-6374(03)00013-7. [DOI] [PubMed] [Google Scholar]
  • 79.McGlauchlen K.S., Vogel L.A. Ineffective humoral immunity in the elderly. Microbes Infect. 2003;5(13):1279–1284. doi: 10.1016/j.micinf.2003.09.001. [DOI] [PubMed] [Google Scholar]
  • 80.Levine M.M., Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 2004;5(5):460–464. doi: 10.1038/ni0504-460. [DOI] [PubMed] [Google Scholar]
  • 81.Kenney R.T., Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines. 2003;2(2):167–188. doi: 10.1586/14760584.2.2.167. [DOI] [PubMed] [Google Scholar]
  • 82.Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005;11(4 Suppl):63–68. doi: 10.1038/nm1210. [DOI] [PubMed] [Google Scholar]
  • 83.Barouch D.H., Santra S., Steenbeke T.D., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998;161(4):1875–1882. [PubMed] [Google Scholar]
  • 84.Kutzler M.A., Robinson T.M., Chattergoon M.A., et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T-cells that are partially independent of CD4 T-cell help. J Immunol. 2005;175(1):112–123. doi: 10.4049/jimmunol.175.1.112. [DOI] [PubMed] [Google Scholar]
  • 85.Li Y., Bleakley M., Yee C. IL-21 influences the frequency, phenotype and affinity of the antigen-specific CD8 T-cell response. J Immunol. 2005;175(4):2261–2269. doi: 10.4049/jimmunol.175.4.2261. [DOI] [PubMed] [Google Scholar]
  • 86.Melchionda F., Fry T.J., Milliron M.J., et al. Adjuvant IL7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest. 2005;115(5):1177–1187. doi: 10.1172/JCI23134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Hainz U., Jenewein B., Asch E., et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine. 2005;23(25):3232–3235. doi: 10.1016/j.vaccine.2005.01.085. [DOI] [PubMed] [Google Scholar]
  • 88.Herndler-Brandstetter D., Cioca D.P., Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise. Wien Med Wochenschr. 2006;156(5–6):130–141. doi: 10.1007/s10354-006-0267-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunosenescence are provided here courtesy of Nature Publishing Group

RESOURCES